183 related articles for article (PubMed ID: 10971105)
1. Growth hormone therapy in achondroplasia.
Seino Y; Yamanaka Y; Shinohara M; Ikegami S; Koike M; Miyazawa M; Inoue M; Moriwake T; Tanaka H
Horm Res; 2000; 53 Suppl 3():53-6. PubMed ID: 10971105
[TBL] [Abstract][Full Text] [Related]
2. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.
Tanaka H; Kubo T; Yamate T; Ono T; Kanzaki S; Seino Y
Eur J Endocrinol; 1998 Mar; 138(3):275-80. PubMed ID: 9539301
[TBL] [Abstract][Full Text] [Related]
3. Molecular defects in achondroplasia and the effects of growth hormone treatment.
Seino Y; Moriwake T; Tanaka H; Inoue M; Kanzaki S; Tanaka T; Matsuo N; Niimi H
Acta Paediatr Suppl; 1999 Feb; 88(428):118-20. PubMed ID: 10102070
[TBL] [Abstract][Full Text] [Related]
4. Growth and growth hormone therapy in children with achondroplasia: a two-year experience.
Stamoyannou L; Karachaliou F; Neou P; Papataxiarchou K; Pistevos G; Bartsocas CS
Am J Med Genet; 1997 Oct; 72(1):71-6. PubMed ID: 9295079
[TBL] [Abstract][Full Text] [Related]
5. The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia.
Tanaka N; Katsumata N; Horikawa R; Tanaka T
Endocr J; 2003 Feb; 50(1):69-75. PubMed ID: 12733711
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone (GH) treatment in achondroplasia.
Yamate T; Kanzaki S; Tanaka H; Kubo T; Moriwake T; Inoue M; Seino Y
J Pediatr Endocrinol; 1993; 6(1):45-52. PubMed ID: 8374688
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for the treatment of achondroplasia.
Yamanaka Y; Ueda K; Seino Y; Tanaka H
Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
[TBL] [Abstract][Full Text] [Related]
8. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y
J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
[TBL] [Abstract][Full Text] [Related]
9. Human growth hormone treatment in prepubertal children with achondroplasia.
Weber G; Prinster C; Meneghel M; Russo F; Mora S; Puzzovio M; Del Maschio M; Chiumello G
Am J Med Genet; 1996 Feb; 61(4):396-400. PubMed ID: 8834055
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone therapy in achondroplasia.
Nishi Y; Kajiyama M; Miyagawa S; Fujiwara M; Hamamoto K
Acta Endocrinol (Copenh); 1993 May; 128(5):394-6. PubMed ID: 8317186
[TBL] [Abstract][Full Text] [Related]
11. [Updated treatment of achondroplasia].
Seino Y
Clin Calcium; 2009 Mar; 19(3):432-6. PubMed ID: 19252254
[TBL] [Abstract][Full Text] [Related]
12. [Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].
Mancilla EE; Poggi H; Repetto G; García C; Foradori A; Cattani A
Rev Med Chil; 2003 Dec; 131(12):1405-10. PubMed ID: 15022403
[TBL] [Abstract][Full Text] [Related]
13. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
[TBL] [Abstract][Full Text] [Related]
14. Treatment of achondroplasia with growth hormone: six years of experience.
Ramaswami U; Rumsby G; Spoudeas HA; Hindmarsh PC; Brook CG
Pediatr Res; 1999 Oct; 46(4):435-9. PubMed ID: 10509364
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of growth hormone therapy for patients with skeletal dysplasia.
Kanazawa H; Tanaka H; Inoue M; Yamanaka Y; Namba N; Seino Y
J Bone Miner Metab; 2003; 21(5):307-10. PubMed ID: 12928832
[TBL] [Abstract][Full Text] [Related]
16. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
Van Pareren Y; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
18. Final adult height in long-term growth hormone-treated achondroplasia patients.
Harada D; Namba N; Hanioka Y; Ueyama K; Sakamoto N; Nakano Y; Izui M; Nagamatsu Y; Kashiwagi H; Yamamuro M; Ishiura Y; Ogitani A; Seino Y
Eur J Pediatr; 2017 Jul; 176(7):873-879. PubMed ID: 28501952
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.
Hertel NT; Eklöf O; Ivarsson S; Aronson S; Westphal O; Sipilä I; Kaitila I; Bland J; Veimo D; Müller J; Mohnike K; Neumeyer L; Ritzen M; Hagenäs L
Acta Paediatr; 2005 Oct; 94(10):1402-10. PubMed ID: 16299871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
